Publication Name	World Journal of Gastroenterology
Manuscript ID	15407
Country	Japan

Received	2014-11-25 20:19
Peer-Review Started	2014-11-26 10:08
To Make the First Decision	2014-12-26 13:24
Return for Revision	2014-12-31 09:08
Revised	2015-01-08 11:15
Second Decision	2015-01-31 09:28
Accepted by Journal Editor-in-Chief	2015-02-02 10:43
Accepted by Company Editor-in-Chief	2015-02-05 17:10
Articles in Press	2015-02-05 17:39
Publication Fee Transferred
Edit the Manuscript by Language Editor	2015-02-27 21:35
Typeset the Manuscript	2015-03-23 16:03
Publish the Manuscript Online	2015-04-07 17:13

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Editorial
Article Title	Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis
Manuscript Source	Invited Manuscript
All Author List	Yoshihisa Takahashi, Keiichiro Sugimoto, Hiroshi Inui and Toshio Fukusato
Funding Agency and Grant Number
Corresponding Author	Yoshihisa Takahashi, Associate Professor, MD, Department of Pathology, Teikyo University School of Medicine, 2-11-1 Kaga, Itabashi-ku, Tokyo 173-8605, Japan. ytakaha-tky@umin.ac.jp
Key Words	Pharmacological therapy; Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis; Vitamin E; Thiazolidinedione
Core Tip	Nonalcoholic fatty liver disease (NAFLD)/nonalcoholic steatohepatitis (NASH) is considered to be a hepatic manifestation of metabolic syndrome. Currently, the principal treatment for NAFLD/NASH is lifestyle modification by diet and exercise. However, establishment of pharmacological therapy is indispensable. Currently, insulin sensitizers (thiazolidinediones) and antioxidants (vitamin E) seem to be the most promising agents for treating NAFLD/NASH, and lipid-lowering drugs, pentoxifylline, angiotensin receptor blockers, and n-3 polyunsaturated fatty acids also have promise. However, there is a lack of consensus regarding the most effective and appropriate pharmacotherapy for NAFLD/NASH. Here, we review the existing and potential pharmacological therapies for NAFLD/NASH.
Publish Date	2015-04-07 17:13
Citation	Takahashi Y, Sugimoto K, Inui H, Fukusato T. Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J Gastroenterol 2015; 21(13): 3777-3785
URL	http://www.wjgnet.com/1007-9327/full/v21/i13/3777.htm
DOI	http://dx.doi.org/10.3748/wjg.v21.i13.3777

Full Article (PDF)	WJG-21-3777.pdf
Full Article (Word)	WJG-21-3777.doc
Manuscript File	15407-Review.docx
Answering Reviewers	15407-Answering reviewers.pdf
Conflict-of-Interest Disclosure Form	15407-Conflict-of-interest statement.pdf
Copyright License Agreement	15407-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate	15407-Language certificate.pdf
Peer-review Report	15407-Peer-review(s).pdf
Journal Editor-in-Chief Review Report	15407-Journal Editor-in-Chief's Review Report.pdf
Scientific Misconduct Check	15407-Scientific misconduct check.pdf
Scientific Editor Work List	15407-Scientific editor work list.pdf